Flow Cytometric Analysis of CD64 Expression Pattern and Density in the Diagnosis of Acute Promyelocytic Leukemia: a Multi-center Study in Shanghai, China

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Nov 9

PMID 29113330

Citations 7

Authors

Min Liu

Xiangqin Weng

Shenglan Gong

Hui Chen

Jing Ding

Mengqiao Guo

Xiaoxia Hu

Jianmin Wang

Jianmin Yang

Gusheng Tang

Affiliations

Soon will be listed here.

Abstract

No unified immunophenotypic profiles and corresponding analytic strategies have been established for the rapid diagnosis of acute promyelocytic leukemia (APL) using flow cytometry (FCM). Here we describe a characteristic immunophenotypic panel that can rapidly and accurately distinguish APL from other types of adult acute myeloid leukemia (AML) using only FCM. By comparing APL cells and non-APL AML cells that share APL common immunophenotypes (CD34CD117HLADR) we found that CD64 was a significant factor that differentiated APL from other AMLs. Further retrospective analyses of 205 APL and 629 non-APL AML patients from different hematology centers showed that either the CD64CD13 CD33MPO (myeloperoxidase) CD11c panel or the CD64CD13 CD33MPO CD11cCD10CD117 SSC (high side scatter signal) panel could distinguish APL from non-APL AML patients with nearly 100% sensitivity, specificity and accuracy. Moreover, relative quantification of CD64 expression enhanced the applicability of our APL diagnostic immunophenotypic panels (ADI-panels) in different hematology centers. Application of the ADI-panels will decrease diagnosis time and improve personalized treatment for APL, a life-threatening disease with very rapid progression.

Citing Articles

Characteristics and Prognosis of "Acute Promyelocytic Leukemia-like" Nucleophosmin-1-Mutated Acute Myeloid Leukemia in a Retrospective Patient Cohort.

Papadopoulou V, Schiavini G, Stalder G, Basset V, Schoumans J, Nabergoj M Biomedicines. 2024; 12(10).

PMID: 39457595 PMC: 11505509. DOI: 10.3390/biomedicines12102282.

Design, optimization, production and activity testing of recombinant immunotoxins expressed in plants and plant cells for the treatment of monocytic leukemia.

Knodler M, Frank K, Kerpen L, Buyel J Bioengineered. 2023; 14(1):2244235.

PMID: 37598369 PMC: 10444015. DOI: 10.1080/21655979.2023.2244235.

Analysis of bacterial spectrum, activin A, and CD64 in chronic obstructive pulmonary disease patients complicated with pulmonary infections.

Fei Z, Wang J, Liang J, Zhou X, Guo M World J Clin Cases. 2022; 10(8):2382-2392.

PMID: 35434072 PMC: 8968607. DOI: 10.12998/wjcc.v10.i8.2382.

Using Antigen Expression of Leukemic Cells for a Fast Screening of Acute Promyelocytic Leukemia by Flow Cytometry.

Ceni-Silva V, Pagnano K, Duarte G, Pellegrini M, Duarte B, Metze K Diagnostics (Basel). 2021; 11(11).

PMID: 34829335 PMC: 8625952. DOI: 10.3390/diagnostics11111988.

Neutrophils: Need for Standardized Nomenclature.

McKenna E, Ui Mhaonaigh A, Wubben R, Dwivedi A, Hurley T, Kelly L Front Immunol. 2021; 12:602963.

PMID: 33936029 PMC: 8081893. DOI: 10.3389/fimmu.2021.602963.

References

Gorczyca W, Sun Z, Cronin W, Li X, Mau S, Tugulea S . Immunophenotypic pattern of myeloid populations by flow cytometry analysis. Methods Cell Biol. 2011; 103:221-66. DOI: 10.1016/B978-0-12-385493-3.00010-3. View

Oldaker T, Wallace P, Barnett D . Flow cytometry quality requirements for monitoring of minimal disease in plasma cell myeloma. Cytometry B Clin Cytom. 2015; 90(1):40-6. PMC: 5404813. DOI: 10.1002/cyto.b.21276. View

Liu Q, Wang M, Hu Y, Xing H, Chen X, Zhang Y . Significance of CD71 expression by flow cytometry in diagnosis of acute leukemia. Leuk Lymphoma. 2013; 55(4):892-8. DOI: 10.3109/10428194.2013.819100. View

Johansson U, Bloxham D, Couzens S, Jesson J, Morilla R, Erber W . Guidelines on the use of multicolour flow cytometry in the diagnosis of haematological neoplasms. British Committee for Standards in Haematology. Br J Haematol. 2014; 165(4):455-88. DOI: 10.1111/bjh.12789. View

Preijers F, van der Velden V, Preijers T, Brooimans R, Marijt E, Homburg C . Fifteen years of external quality assessment in leukemia/lymphoma immunophenotyping in The Netherlands and Belgium: A way forward. Cytometry B Clin Cytom. 2015; 90(3):267-78. DOI: 10.1002/cyto.b.21266. View

Horna P, Zhang L, Sotomayor E, Lancet J, Moscinski L . Diagnostic immunophenotype of acute promyelocytic leukemia before and early during therapy with all-trans retinoic acid. Am J Clin Pathol. 2014; 142(4):546-52. PMC: 5744863. DOI: 10.1309/AJCPPOKEHBP53ZHV. View

Dong H, Kung J, Bhardwaj V, McGill J . Flow cytometry rapidly identifies all acute promyelocytic leukemias with high specificity independent of underlying cytogenetic abnormalities. Am J Clin Pathol. 2010; 135(1):76-84. DOI: 10.1309/AJCPW9TSLQNCZAVT. View

Dimov N, Medeiros L, Ravandi F, Bueso-Ramos C . Acute promyelocytic leukemia at time of relapse commonly demonstrates cytogenetic evidence of clonal evolution and variability in blast immunophenotypic features. Am J Clin Pathol. 2010; 133(3):484-90. DOI: 10.1309/AJCPJ7K0AWMBHMAI. View

Borowitz M, Wood B, Devidas M, Loh M, Raetz E, Salzer W . Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. Blood. 2015; 126(8):964-71. PMC: 4543229. DOI: 10.1182/blood-2015-03-633685. View

10.

Takenokuchi M, Kawano S, Nakamachi Y, Sakota Y, Syampurnawati M, Saigo K . FLT3/ITD associated with an immature immunophenotype in PML-RARα leukemia. Hematol Rep. 2013; 4(4):e22. PMC: 3555210. DOI: 10.4081/hr.2012.e22. View

11.

Gorczyca W . Acute promyelocytic leukemia: four distinct patterns by flow cytometry immunophenotyping. Pol J Pathol. 2012; 63(1):8-17. View

12.

Ahmad E, Akl H, Hashem M, Elgohary T . The biological characteristics of adult CD34+ acute promyelocytic leukemia. Med Oncol. 2011; 29(2):1119-26. DOI: 10.1007/s12032-011-9895-y. View

13.

Zhang L, Zhu X . Epidemiology, diagnosis and treatment of acute promyelocytic leukemia in children: the experience in china. Mediterr J Hematol Infect Dis. 2012; 4(1):e2012012. PMC: 3340987. DOI: 10.4084/MJHID.2012.012. View

14.

Bene M, Grimwade D, Haferlach C, Haferlach T, Zini G . Leukemia diagnosis: today and tomorrow. Eur J Haematol. 2015; 95(4):365-73. DOI: 10.1111/ejh.12603. View

15.

Grimwade D, Freeman S . Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?. Blood. 2014; 124(23):3345-55. DOI: 10.1182/blood-2014-05-577593. View

16.

Lin P, Hao S, Medeiros L, Estey E, Pierce S, Wang X . Expression of CD2 in acute promyelocytic leukemia correlates with short form of PML-RARalpha transcripts and poorer prognosis. Am J Clin Pathol. 2004; 121(3):402-7. DOI: 10.1309/XC8P-9M8N-KQDT-38LB. View

17.

Dunphy C, Tang W . The value of CD64 expression in distinguishing acute myeloid leukemia with monocytic differentiation from other subtypes of acute myeloid leukemia: a flow cytometric analysis of 64 cases. Arch Pathol Lab Med. 2007; 131(5):748-54. DOI: 10.5858/2007-131-748-TVOCEI. View

18.

Foucar K, Anastasi J . Acute Myeloid Leukemia With Recurrent Cytogenetic Abnormalities. Am J Clin Pathol. 2015; 144(1):6-18. DOI: 10.1309/AJCPI9C8UILYQTNS. View

19.

Yoshii M, Ishida M, Yoshida T, Okuno H, Nakanishi R, Horinouchi A . Clinicopathological features of acute promyelocytic leukemia: an experience in one institute emphasizing the morphological and immunophenotypic changes at the time of relapse. Int J Clin Exp Pathol. 2013; 6(10):2192-8. PMC: 3796242. View

20.

Bjorklund E, Matinlauri I, Tierens A, Axelsson S, Forestier E, Jacobsson S . Quality control of flow cytometry data analysis for evaluation of minimal residual disease in bone marrow from acute leukemia patients during treatment. J Pediatr Hematol Oncol. 2009; 31(6):406-15. DOI: 10.1097/MPH.0b013e3181a1c0e8. View